Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Christine Varon
 -- 5048 2022-05-12 22:23:08 |
2 layout
Camila Xu
 Meta information modification 5048 2022-05-13 04:43:30 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Seeneevassen, L.; Dubus, P.; Gronnier, C.; Varon, C. Hippo in Gastric Cancer. Encyclopedia. Available online: https://encyclopedia.pub/entry/22890 (accessed on 03 July 2024).
Seeneevassen L, Dubus P, Gronnier C, Varon C. Hippo in Gastric Cancer. Encyclopedia. Available at: https://encyclopedia.pub/entry/22890. Accessed July 03, 2024.
Seeneevassen, Lornella, Pierre Dubus, Caroline Gronnier, Christine Varon. "Hippo in Gastric Cancer" Encyclopedia, https://encyclopedia.pub/entry/22890 (accessed July 03, 2024).
Seeneevassen, L., Dubus, P., Gronnier, C., & Varon, C. (2022, May 12). Hippo in Gastric Cancer. In Encyclopedia. https://encyclopedia.pub/entry/22890
Seeneevassen, Lornella, et al. "Hippo in Gastric Cancer." Encyclopedia. Web. 12 May, 2022.
Hippo in Gastric Cancer
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cancers14092282

The Hippo signalling pathway is one of the most crucial and complex ones in physiology, and there is no doubt that the regulatory mechanisms it possesses are various. The role of this signalisation process in tissue homeostasis makes it keen to lead to cancerous processes when dysregulated. 

gastric cancer hippo YAP TAZ cancer stem cells

1. The Hippo Pathway

1.1. Overview

The Salvador-Warts-Hippo pathway (SAV1-LATS1/2-MST1/2 in mammals) is the key regulator of organ size and tissue homeostasis in physiology. Ever since its discovery in Drosophila [1][2], described as “hippopotamus phenotype” (contributing to its name), where its deregulation induces a dramatic tissue overgrowth, this evolutionary conserved pathway has been described in divers physiological and pathological processes; from cell growth, proliferation, cell-cell contact, cell density and cell polarity control, stemness, shear stress, tissue homeostasis, and repair and regeneration, to cancer [3][4][5][6][7][8][9][10][11][12][13]. Genetic screenings for genes involved in cell growth led to the discovery of its different members [5][6][14]. This highly conserved pathway in mammals is made up of two central groups of elements driving its role: 1) a serine-threonine kinase core comprising of Mammalian Sterile-20 such as 1/2 (MST1/2) and Large tumour suppressor 1/2 (LATS1/2) kinases and, 2) a transcriptional module containing Yes-associated protein (YAP) [15][16][17] and/or a Transcriptional co-activator, with a PDZ binding motif (WWTR1 or TAZ) (Figure 1).
Figure 1. Hippo/YAP/TAZ-TEAD signalling pathway. Schematical representation of Hippo signalisation network. Regulation of YAP/TAZ effectors by LATS are represented by the blue arrows, endogenous YAP/TAZ-TEAD inhibitors in green, and Hippo kinases regulators and partners in pink.
YAP/TAZ are transcriptional co-activators. They do not possess DNA-binding motifs and need DNA-binding partners to accomplish their roles. The major ones are TEA domain family member 1–4 (TEAD1-4), also known as the Transcriptional enhancer factor (TEF) in mammals, and Scalloped (Sd) in Drosophila [18][19]. TEAD fixation by YAP/TAZ is significant in the mediation of its biological functions. Screening of the human transcription factor library, coupled with luciferase transcription reporter assays and/or yap co-transfection, allowed the identification of TEADs as the major actor of YAP binding to gene promoters and of YAP-induced transcriptional activity [6][19].
Studies show that YAP/TAZ are the effectors carrying the functional activity of the pathway. Mutations of Yorkie (Yki), YAP/TAZ ortholog in Drosophila, lead to decrease in proliferation, while the gigantism phenotype and liver tissue expansion are observed with its overexpression, coinciding with the phenotype observed upon Hippo kinases mutation. YAP deletion in mice decreases cell overgrowth phenotype caused by a lack of MST1/2 [5][8]. Active YAP mutant transgenic expression or dysregulation, through deletion of Hippo kinase members at the embryonic stage, leads to the hyperproliferation of cardiomyocytes and heart enlargement [20][21][22][23].
In addition, YAP1 overactivation in the intestines causes enlargement of the pool of multipotent undifferentiated progenitor cells, which undergo differentiation once YAP induction is ceased [8][11]. YAP inhibition also re-establishes cell-contact inhibition. Strict control of these effectors is, thus, required for proper tissue homeostasis.

1.2. Regulation Mechanisms

Hippo pathway regulators intervene at different levels for the maintenance of proper tissue homeostasis (Figure 1).

1.2.1. YAP/TAZ Effectors Regulation

Hippo effectors are, indeed, tightly controlled by upstream members of the pathway, the hippo kinases, and their regulatory partners, Salvador Family WW Domain Containing Protein 1 (SAV1) and MOB Kinase Activator 1A/B (MOB1A/B), playing a role in the activation of MST1/2 and LATS1/2, respectively. Phosphorylation cascade of members of this kinase core induces the phosphorylation of YAP/TAZ effectors and, thus, represses their nuclear localisation and activity [3][6][9][18][24]. This is demonstrated in hippo kinases inhibition models, where nuclear accumulation of the effectors is observed [9][25].
Among the inhibition mechanisms are cytoplasm sequestration or nuclear exclusion mechanisms. YAP/TAZ are active in the nucleus and their nuclear accumulation is, thus, elemental for their function as co-transcription factors. Hippo kinase LATS1/2 phosphorylate YAP and TAZ on Ser-127 (p-YAPSER127) and Ser-89 (p-TAZSER89) residues, respectively, allowing their binding to 14-3-3 proteins, thus retaining them in the cytoplasm [3][18]. In addition, 14-3-3 proteins knock-down (KD) induces nuclear accumulation, which is consistent with this observation.
Other 14-3-3 proteins-independent mechanisms also exist [25]. For example, LATS1/2 also phosphorylates YAP and TAZ on Ser-381 and Ser-311, respectively, modulating their protein stability, by inducing their polyubiquitination, and their addressing to the proteasome, for degradation. Indeed, studies have shown that TAZ Ser-311 phosphorylation by LATS1/2 can prime it to be further phosphorylated on Ser-314 on their phosphodegron motif by Casein kinase 1 (CK1), allowing interaction with β-TrCP, and, then, with SCF E3 ubiquitin ligases, to be directed to the proteasome for degradation [10][26]. This effector inhibition mechanism is absent in the Drosophila model.
Furthermore, YAP/TAZ contains a COOH-terminal domain, allowing interaction with proteins having PDZ binding domains [3][18][27]. This domain is important for YAP/TAZ regulation. Its absence causes cytoplasmic re-localisation and activity inhibition. YAP and TAZ are able to fixe Zonula occludens-2 protein (ZO-2) (and also ZO-1 for TAZ) and co-localise with it in the nucleus [28][29]. In addition, Vestigial-like 1-4 (VGLL1-4) contain Tondu domains (TDU), which have the capacity of binding TEAD. In so doing, VGLL4, for example, is able to inhibit YAP-TEAD1 interaction, and target TEAD1 for degradation [30]. Likewise, Runt-related transcription factor 3 (RUNX3) physically interacts with TEAD at its N-terminal region and, consequently, stops YAP from fixing to it and reduces its DNA-binding capacity as well as the downstream signalling [31].
YAP/TAZ-TEAD regulation is, therefore, most of the time achieved via the hippo kinase members, whether inhibiting their function or not.

1.2.2. Hippo Kinase Core and Upstream Partners Regulation

The Hippo kinases are also very well regulated, allowing them to sense the need to exert their inhibitory effect on YAP and TAZ. Among the major regulators of the Hippo pathway are mechanical cues such as cell density, cell-cell adhesions, and apico-basal polarity [3][32]. Proteins involved in the maintenance of these cellular events are, thus, implicated in Hippo regulation.
Merlin, coded by neurofibromatosis gene NF2, is an essential regulator of Hippo kinases. It is localised at tight and adherens junctions, when cells are at high density and induce activation of core kinases, which in turn inhibit YAP/TAZ effectors to limit cell proliferation [33][34]. Merlin induces YAP phosphorylation by LATS by several means: it (1) binds with LATS, transporting it to the cell membrane and stimulating a complex formation with MST and SAV and its further activation; (2) promotes the assembly of scaffold proteins to facilitate LATS-YAP interaction and phosphorylation. Actin disruption can activate this Merlin-dependent process [35]. Merlin is critical in liver homeostasis and stem cell niche regulation [36].
Another important protein in the maintenance of cell and tissue integrity and, thus, having a role in the regulation of the Hippo pathway, is Scribble, an adaptor protein, which is important in cell polarity. It is localised at the cell membrane and, like Merlin, is able to assemble a complex, here made of MST, LATS, and TAZ, which is necessary for LATS activation and the consequent phosphorylation cascade [37].
Furthermore, apical proteins such as Crumbs and the Angiomotin family (AMOTs), as well as cadherins-actin cytoskeleton linker proteins such as α-Catenin, are involved in YAP/TAZ regulation by managing their localisation through phosphorylation [38][39][40][41].
Hippo pathway regulation can also imply cell surface receptors such as G-protein coupled receptors (GPCRs) [32] and the Leukaemia Inhibitory Factor receptor (LIFR) [42][43], part of the JAK/STAT signalling pathway. In addition, AMOTp130 isoform can also act as substrate for LATS1/2. AMOTp130-LATS1/2 signalling is inhibited by serum LPA, through activation of Gαs-coupled GPCR signalling. In this context, the LATS1/2 Ser-175 phosphorylation of AMOTp130 can disrupt the latter’s interaction with F-actin and decrease stress fibres and focal adhesions. In so doing, LATS1/2 and AMOTp130SER175 repress endothelial cell migration in vitro and angiogenesis in zebrafish models [44].
YAP/TAZ activation proteins also exist, for example, the Protein phosphatase 2A (PP2A) complex STRIPAK, which exerts a negative control on Hippo kinases through their de-phosphorylation, thus inducing YAP/TAZ [45].

1.3. Hippo and Cancer

This pathway’s implication in cellular and tissular vital processes makes its dysregulation highly critical. Despite the numerous levels of regulation, the hippo pathway is found to be involved in various cancers. In Drosophila, mutations altering the function of Hippo kinases induce hyperproliferation and decreased apoptosis, leading to the appearance of tumours. This first demonstrated the tumour suppressor characteristics of Hippo kinases [3][12]. The liver tissue enlargement observed after mutation of Hippo kinases can be attributed to uncontrolled cell growth observed in cancers [5][8]. Furthermore, activation of YAP drosophila homologue Yki led to unrestrained growth of cells, which is one prerequisite for tumour formation [5].
Studies relate the role of YAP/TAZ hyperactivation in many cancers. The critical genes regulated by these transcriptional co-activators make it easy to go over to the dark side when disturbed, tending towards some cancer hallmarks such as sustaining proliferative signalling, resisting cell death, activating invasion and metastasis, and tumour-promoting inflammation, among others [46][47]. Though it has high functional potential, activating mutations of YAP gene are not described in cancer. Nonetheless, it is found to be localised on the 11q22 amplicon, amplified in various cancers, which could explain its hyperactivity [48]. Furthermore, inactive mutations or epigenetic regulations of Hippo kinases or close members are often observed in tumours [48].
Plouffe et al. show that YAP and its paralogue TAZ have distinct roles apart from their overlapping functions [49]. Hippo target genes induction can also differ depending on the effector involved. For example, CTGF and CYR61 are regulated by both YAP and TAZ, since serum-induced stimulation of these genes is decreased in YAP/TAZ-KO cells. Furthermore, YAP deletion seems to have a greater effect than TAZ deletion on CTGF and CYR61 expression, though to a lower extent for the latter. This was demonstrated in three different cell lines, including HeLa cervical cancer, MCF7 breast cancer, and HEK293A human embryonic kidney cells. YAP KO, TAZ KO, and YAP/TAZ KO caused the induction of LGR5, showing the role of both effectors in LGR5 repression. YAP and YAP/TAZ KO demonstrated the role of YAP in cell spreading, size, granularity, glucose uptake, proliferation, and migration, which decreased after its deletion compared to wild-type (WT) cells that resembled TAZ KO cells [49]. Interestingly, LATS1/2 KO cells gave the opposite of what was observed in YAP KO and YAP/TAZ KO cells. Nevertheless, this research was carried out on HEK293A human embryonic kidney cells in which, despite the higher TAZ mRNA expression than that of YAP, the highly dynamic regulation of TAZ made its protein less than twice that expressed by the YAP protein [49]. This could explain why YAP deletion affects more cell size and physiology than TAZ deletion. YAP different regulation of CTGF is, nonetheless, a solid fact, and the other YAP-dependent target genes identified were AMOTL2 and Fos-like antigen 1 (FOSL1).
Colorectal (CRC), NSCLC, and breast cancers, as well as hepatocellular carcinomas (HCC) and melanomas, for example, present high expression of YAP or TAZ. In CRC, circular RNA circPPP1R22A induces YAP activation, causing tumour growth and metastasis, which decreases in presence of peptide 17, an inhibitor of YAP [50].
In breast-cancer-induced bone marrow metastasis, hypoxic environments influence HIF-1α interaction with TAZ. Nuclear HIF-1α is associated with the epithelial-to-mesenchymal transition (EMT) process and interaction with Hippo effectors, and is negatively regulated by LATS1/2 [51][52]. YAP interaction with ZEB1, as discussed before, contributes to the expression of target gene having a role in poor survival of patients, therapy resistance, and increased metastasis in breast cancer [53].
Furthermore, breast cancer bone marrow metastasis can also be induced by crosstalk between ROR1-Her3 and Hippo-YAP, through inactivation of MST1 [54]. Indeed, the phosphorylation of HER3 at Tyr1307 by the ROR1 tyrosine kinase receptor induces the methylation of MST1 at Lys59 and its deactivation. MOB1a/b deletion causes breast [55] and lung tumours [56]. Furthermore, it has been demonstrated that breast cancer cells are able to promote YAP/TAZ expression and activity in cancer associated fibroblasts (CAFS), one of the components of the tumour micro-environment. This has, as a consequence, the remodelling and stiffening of extracellular matrix, related to CAFs’ pro-tumorigenic roles, as well as the angiogenesis improvement required for tumour growth [57].
YAP and TAZ overexpression in NSCLC are related to tumour development, progression, and a patient’s poor prognosis. Hyperactivation mutations of YAP are observed in this type of cancer, as is the downregulation of LATS2 in 60% of cases [58]. miR-135 is found to be highly expressed in NSCLC and is associated with poor survival outcomes. This microRNA is capable of increasing invasive and migration properties of cancer cells in vitro and metastasis in vivo, through the targeting of hippo kinase core members [59]. Moreover, YAP is able to activate EMT transcription factor Slug, which in turn inhibits the BMF pro-apoptotic factor. Cells enter a senescence-like dormant state and counter the drug-induced apoptosis [60]. RAF/MEK/ERK is found to contribute to NSCLC through YAP modulation, since the anti-ERK1/2 siRNA strategy discussed earlier led to a decrease in migration and an invasion of NSCLC cells, along with the decrease in YAP protein expression observed [61].
In the liver, inducible YAP expression as well as deletion of NF2, SAV1, or MST1/2 leads to hepatomegaly and, further, to liver tumours [8][9][36][62]. HCC is characterised by the high expression of miRNA-665 and miRNA-3910, which have inhibitory effects on hippo kinases such as MST1, leading to decreased apoptosis and increased cell proliferation, migration, invasion, and EMT [18][63][64][65]. On the contrary, miRNA-195, having a tumour suppressor role, is decreased in HCC, and this is associated with the low survival rate of patients [66][67]. YAP activation is an early event in HCC, with the PDZ-binding domain being crucial for the activation of the cell proliferation gene CTGF [12]. In this type of cancer, CREB can promote transcriptional activity of YAP [68][69]. In addition, MEK1-YAP1 interaction leads to increased cell proliferation and maintenance of transformed neoplastic phenotype [70].
In melanomas, YAP is sufficient and necessary for invasion of cells and appearance of spontaneous metastasis [71]. Target genes involved in this phenomenon are AXL, THBS1, and CYR61. In skin cancers, deletion of MST1/2, surprisingly, does not have any flagrant effect, though YAP activation is implicated in the keratinocytes’ hyper-proliferation and the squamous cell carcinoma that is overcome, following the deletion of the CTNNA1 encoding α-catenin [40]. Furthermore, methylation of the LATS1/2 promoter contributes to oral squamous cell carcinoma (OSCC) [72][73]. In addition, in pancreatic cancer, YAP1 cooperates with K-RAS and induces tumour survival and EMT, which is involved in cancer cell metastasis [74].
Β-catenin-YAP cooperation, as explained above, is important in the tumorigenicity of β-catenin active cells, namely SW480, SNU-C1, HCT116 colon cancer cells, AGS GC cells, and A549 lung cancer cells, among others [75]. Interestingly, conversely to what expected, neither β-catenin partner TCF2 nor YAP partner TEAD was implicated in this pro-tumorigenic effect [76][77]. TBX5 transcription factor is the one mediating the pro-proliferation signal by inducing the transcription of BCL2L1 and BIRC5, and YES1 is essential in this process.
The Hippo pathway also plays an important role in the resistance to therapy of many cancers, such as gliomas, retinoblastomas, endometrial, bladder cell, pancreatic, and ovarian cancers [78][79][80][81][82][83]. YAP-TEAD is involved in NSCLC cells’ escape to Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment [60]. Indeed, resistant cells are found to have high expression and activity of YAP/TEAD.
Another dysregulation observed in cancers and linked to the Hippo pathway is EMT, which involves a loss of epithelial architecture. This affects Hippo membrane regulators such as Scribble, which gets delocalised, thus activating YAP/TAZ and contributing to tumorigenesis and CSCs [37]. This has also been demonstrated in breast cancer cells lacking E-cadherin, having a role in epithelium integrity, and where the Scribble delocalisation phenotype can be counteracted by Hippo kinases reactivation [42]. Indeed, a perturbed E-cadherin/α-Catenin complex leads to decreased YAP phosphorylation and induced cancer-related transcriptional activity.
The role of the Hippo pathway in tissue homeostasis is greatly responsible for tumour appearance and maintenance when dysregulated. Cancer is a complex disease, and YAP/TAZ oncogenic ability seems to be involved in diverse parts of this ailment, from tumour initiation to tumour-immune cells’ crosstalk, extracellular matrix remodelling, and dissemination [3][7][12][84][85]. Disbalance of Hippo-YAP/TAZ regulation is at the root of many cancers, amongst which is gastric cancer (GC), on which researchers will focus in the next part of this research.

2. Hippo Pathway in Gastric Carcinogenesis

2.1. Hippo Pathway in Helicobacter-Mediated Gastric Carcinogenesis

GC is a major health concern, and the Hippo pathway is implicated, since the very beginning of gastric carcinogenesis induced by chronic infection with Helicobacter pylori (H. pylori) is classified as a type 1 carcinogen and the principal cause of GC [86][87][88][89].
MST1/2 and LATS1/2 Hippo kinases are found downregulated, and YAP/TAZ effectors upregulated, in GC [90][91][92] (Figure 2). Nuclear expression of YAP/TAZ, related to their activity, is associated with a poor prognosis in GC patients, particularly in those with intestinal-type GC for YAP [32][42][93][94][95][96]. YAP is found overactivated in gastric carcinogenesis, and H. pylori infection stimulates both Hippo downstream effectors YAP/TAZ, as demonstrated by transcriptomic analyses in gastric epithelial cells after H. pylori infection [86]. This effect is abrogated by infection with CagA-mutant strains, showing the role of H. pylori in YAP hyperactivation and, most particularly, of the bacterium’s CagA oncoprotein.
Figure 2. YAP expression in GC compared to non-tumorous gastric mucosa. Representative images of total-YAP immunostaining in GC patients’ tissues from our experiments. (A), non-tumorous gastric mucosa and adjacent GC from the same patient. (C,E) are representative images of diffuse and intestinal types GC cases, respectively; magnifications highlight YAP subcellular localisation, with nuclear accumulation in GC. Scale bars, 50 µm. KMplot™ analysis using KMplotter software (Kaplan-Meier plotter) [97] showing bad prognosis of patients with GC all subtypes included (B), diffuse (D), and intestinal (F) subtypes, when YAP is highly expressed.
Furthermore, YAP inhibition affected H. pylori-induced EMT, demonstrating the pathway’s contribution to H. pylori-related gastric carcinogenesis. Molina et al. have shown that H. pylori infection of gastric epithelial cells induces the expression of both YAP1 and LATS2 from the gastritis stage (early stage of the Correa’s cascade of H. pylori-induced gastric carcinogenesis) [43][86], which continues increasing at the intestinal metaplasia and GC stages [86]. YAP1-TEAD pro-proliferation and pro-survival-related genes were found to be increased after infection. Time-course infection with H. pylori showed that YAP1 is activated as early as 2h after the bacterial infection and causes an increase in target genes, including LATS2 acting as a regulatory feedback loop, thus controlling H. pylori-induced YAP/TAZ activation and cell growth from 5 to 24 h post-infection. An equilibrium, thus, exists for the maintenance of YAP1 proper balance as well as proper epithelial cell differentiation and survival in response to H. pylori infection, to limit epithelial cell identity loss [86].
Furthermore, nuclear YAP/TAZ-TEAD activity is induced following H. pylori infection of GC cells. TAZ is co-expressed and found co-localised with EMT-related transcriptional factor ZEB1 in cells having a mesenchymal phenotype, and at the invasive fronts of gastric tumours. TAZ-ZEB1 cooperation in H. pylori-induced GC is demonstrated by TAZ silencing, which decreases ZEB1 expression and EMT, as well as invasion and cancer stem cell (CSC) tumoursphere formation properties acquired by GC cells after H. pylori infection [87]. This could be related to direct TAZ interaction with the promoter of ZEB1, as described in RPE cells [98].

2.2. Hippo Pathway in GC and CSCs

CSCs’ presence in tumours is a major problem in GC, like in many other solid tumours [88][99][100][101][102][103][104]. CSCs correspond to a subpopulation of cells within tumours at the origin of tumour initiation, growth, dissemination, and resistance to current treatments. They have asymmetrical division properties, allowing their self-renewal and parallel proliferation and differentiation, at the base of tumour heterogeneity. Bessède et al. reported that, during the gastric carcinogenesis cascade, H. pylori infection induces the emergence of CD44+ cells carrying CSC properties, through the EMT process [105]. Giraud et al. recently demonstrated through transcriptomics analysis that CD44+ gastric CSCs have a Hippo-pathway-rich signature, with an overexpression of effectors and target genes such as AREG, CCND1, CDX2, CYR61, BIRC5, ID1, IGFBP3, JAG1, LATS2, SMAD7, and MYC [106]. Interestingly, TEAD1/4 were also found upregulated in CD44+ cells compared to CD44-non-CSCs, while TEAD inhibitors, VGLL4 and RUNX3, were downregulated. Furthermore, the researchers also demonstrated that residual chemotherapy-treated cells, which are the most resistant ones, present higher expression of YAP1, TAZ, CYR61, and CTGF, all associated to high YAP/TAZ-TEAD activity, compared to non-treated cells.
Fujimoto et al. have shown that Protease-activated receptor 1 (PAR1) stimulation sustains cells with stem-like properties, and induces cell invasion and EMT through inhibition of LATS via Rho A GTPase [107]. PAR1 induces Rho A-induced inhibition of LATS1/2 phosphorylation, leading to activated YAP. Another receptor, Peroxisome proliferator-activated receptor δ (PPAR δ), is found to interact with YAP1, inducing the transcription and upregulation of SOX9, a gastrointestinal stem cell marker, in premalignant lesions [108]. SOX9 induces CSC properties in non-cancerous cells [109], promotes invasion and metastasis, and is overexpressed in patients at advanced stages of GC [11].
Gastric carcinogenesis process was also studied independently of H. pylori infection. Overexpression of hippo effectors, through LATS1/2 knockout (KO) in mice pyloric stem cells, generated transformation of mice normal gastric epithelium to low-grade intraepithelial neoplasia, followed by intramucosal carcinoma [110]. YAP/TAZ were found to initiate GC via MYC as a downstream mediator and direct transcriptional target of YAP [110]. Inhibition of MYC interfered with YAP/TAZ-induced carcinogenesis.
Another study showed LATS1 low expression in GC patients, and this was correlated with lymph node metastasis, poor prognosis, and tumour relapse [111]. LATS1 is found to decrease GC cell proliferation and invasion in vitro, and tumour growth and metastasis in vivo, by inhibiting YAP nuclear translocation and, thus, expression of pro-proliferative and pro-invasive target genes, among which are YAP, CTGF, PCNA, MMP-2, and MMP-9. TAZ overexpression, particularly in diffuse type GC, is associated with EMT profile and low survival of patients [43][106][112].
RUNX3 has been shown to be inactivated in about 60% GC. Subsequently, the tumour suppressor effect of this TEAD interactor on the YAP-TEAD complex is affected in GC, and hyperactivation is noted [31]. The RUNX3 mutation in GC impairs its activity towards a pro-YAP signalling phenotype. Likewise, RUNX2 is implicated in gastric carcinogenesis through the Hippo pathway. It is highly expressed in GC early stages and predicts poor prognosis [113][114]. Ectopic RUNX2 expression is implicated in GC invasion and metastasis process through binding to CXCR4 promoter, thus inducing the expression of CXCR4 [113]. It also induces tumoursphere formation and tumour initiation, showing an effect on the gastric CSC population [113]. CXCR4′s role is also described in CSC and metastasis in GC, as well as in pancreatic, breast, and colorectal cancer [115][116][117][118][119].
Zhou et al. show the role of methyltransferase 3 (METTL3), a major component of the m6A methyltransferase complex, in gastric carcinogenesis [120]. It is highly expressed in GC cases versus non-tumoral tissues. METTL3 overexpression and KD show its role in GC cell proliferation, migration, and invasion in vitro and tumour growth in vivo. Interestingly, METTL3 positively controls YAP1 expression, which could explain its effects [120].
Moreover, Angiomotin Like 1 (AMOTL1) has been shown to interact with YAP1 and promote its nuclear translocation and its activity, thus contributing to gastric carcinogenesis [121]. The hippo pathway is also involved in Fibroblast growth factor receptor type 2 (FGFR2) gastric oncogenesis, through indirect YAP1 activation via the MAPK-c-Jun pathway [122]. Overexpression of transcriptional core TEAD1/4 and YAP/TAZ targets CYR61 and CTGF is related to metastasis and bad prognosis. Furthermore, Tang et al. demonstrate a mechanism by which MST1/2 is turned off in some GC cases. Indeed, STRN3 was discovered as a PP2A regulatory subunit and was found to be able to recruit MST1/2, thus promoting its dephosphorylation and the consequent hippo effectors hyperactivation. dSTRIPAK forms part of the STRN3 molecule family, whose expression in induced in GC and associated with YAP activation and bad prognosis [123].
Additionally, microRNAs are also seen to intervene in the hippo pathway’s dysregulation in GC. MiR-125a-5p upregulates TAZ, TEAD2, and, therefore, their target genes, and stimulates cell survival, EMT, invasion, and tumour growth [64]. MiR-125a-5p is found in high levels at late stages of GC and co-expresses with TAZ and TEAD2. Similarly, miR-375 modulation is implicated in GC. Promoter methylation and histone deacetylation represses miR-375 expression in this disease, and this is associated with bad prognosis and lymph node metastasis [124]. Kang et al. show that miR-375 directly targets YAP1, TEAD, and CTGF, and that YAP1 re-expression partly stalls miR-375 tumour-suppressive effects. Furthermore, CTGF-KD demonstrates the same effects as YAP1-silencing and miR-375 ectopic expression on gastric tumours, demonstrating the role of Hippo effectors and their targets in GC. MiR-372 and MiR-373 are found to be implicated in GC cells AGS proliferation through inhibition of LATS2 gene expression [125].
Moreover, long noncoding RNAs (lncRNAs) have been demonstrated as having a role in hippo-pathway-induced gastric carcinogenesis. LncRNA RP11-323N12.5 is the most highly expressed lncRNA in GC, according to the TCGA database. RP11-323N12.5 is found to be correlated to YAP1 expression and to regulate it by acting on its promoter [126]. In so doing, it exerts pro-tumoral and pro-immunosuppressive functions. It is also regulated by YAP1/TAZ-TEAD transcription complex.
Besides, lncRNA acv3UTR is also found to be upregulated in GC. Ectopic expression of acv3UTR in GC cells demonstrated its role in cell growth promotion [127], through its negative effect on tumour suppressor miR-590-5p. Its expression correlates with that of YAP1. In addition, lncRNA LINC00649, enriched in GC, is found to induce cell proliferation, migration, and EMT in vitro, as well as tumorigenesis in vivo [128]. It is able to act on miR-16-5p, which is connected to YAP1 mRNA at the 3′UTR region. By doing so, it blocks the action of hippo kinases, which no longer phosphorylate YAP, and contributes to the expression of its pro-tumoral target genes [128]. On the contrary, Sun et al. identified lncRNA LATS2-AS1-001, which has an anti-tumoral effect in GC, through binding to the Enhancer of zeste homolog 2 (EZH2). This leads to LATS2 upregulation and YAP1 phosphorylation, thus decreasing cell viability, migration, and invasion. Apparently, this lncRNA is under-expressed in GC, which disables its effects [129].
Studies also show a relationship between cell metabolism and hippo-induced gastric carcinogenesis. Indeed, Liu et al. have shown the contribution of a nucleotide sugar transporter Solute carrier family, 35 B4 (SLC35B4), as having a crucial role in macromolecule glycosylation in GC [130]. The YAP1-TEAD complex directly activates SLC35B4, which induces cell proliferation in vitro and in vivo. It is more expressed in cancerous tissues compared to non-cancerous ones and is related to poor prognosis through YAP1′s action. In addition, Acylglycerol kinase (AGK), a lipid kinase involved in the production of physiological lysophosphatidic acid (LPA) and phosphatidic acid (PA), has been recognised for its pro-tumoral role when highly expressed [131]. It induces proliferation, invasion, and EMT phenotype in GC cells, effects that were abrogated by its KD. YAP1 plays a positive role on its regulation through binding to TEAD and to AGK’s promoter. In turn, in a positive feedback loop manner on YAP-TEAD, AGK inhibits hippo kinases, thus promoting YAP nuclear translocation and activity [131].

2.3. Hippo Pathway in GC Resistance to Therapy

The Hippo pathway has also been shown to have a role in therapy resistance in GC, like in many other cancers. There is, unfortunately, no targeted therapy in GC, except for Trastuzumab, which is approved for the treatment of HER2+ metastatic GCs. However, resistance mechanisms have been discovered that are also found at this level, rendering the search for other targets even more vital. Trastuzumab-resistant cells are found to have an overexpression of HER4, phosphorylated-HER4 (p-HER4), and vimentin (VIM), a mesenchymal phenotype marker, and a decrease in epithelial markers. Shi et al. demonstrate that in these cells, HER4 acts on its target YAP1 and induce the expression of genes involved in EMT and proliferation, leading to higher cells migration and growth as well as a decrease in HER2 and E-cadherin expression, leading to HER2-therapy resistance and contributing to mesenchymal phenotype acquisition [132]. Moreover, YAP stimulates GC cell proliferation, while its KD enhances cells’ sensitivity to cisplatin, showing the role of hippo effectors in GC chemoresistance [133]. In this research, the researchers showed that this effect passes through regulation of EGFR/AKT/Extracellular signal-regulated kinase ½ (ERK1/2) by YAP. TAZ overexpression, particularly in diffuse type GC, is associated with the EMT profile, resistance to chemotherapy, and low survival of patients [134].
Interestingly, studies show that YAP and TAZ are not always expressed concomitantly in GC cells [86][87][135]. TAZ is found to be more expressed in gastric signet ring cells carcinomas (SRCC), a poorly differentiated type of GC, usually attributed to Lauren-diffuse-type GC. This type of GC is of a particularly bad prognosis, and this could be related to its high TAZ expression, which is also found to be higher in other poorly differentiated tumours compared to well-differentiated ones such as the Lauren intestinal type. Tiffon et al. demonstrated that in the SRCC GC cell line MKN45 and poorly differentiated GC patient-derived xenograft cells, TAZ is overexpressed and overactivated, controlling the expression of TAZ-TEAD target genes, including CYR61 and AXL among others, and of the EMT main transcription factor ZEB1, which decrease in TAZ KD cells. TAZ is also related to GC cells’ EMT phenotype and invasiveness in this context [87]. Diffuse-type GC can also be characterised by low KRT17 intermediate filaments expression. This decreased KRT17 expression causes E-cadherin loss, EMT phenotype arousal, and metastasis in GC cells. Indeed, loss of intermediate filaments promotes cytoskeleton remodelling and reorganisation, which activates YAP and induces IL6 expression linked to increased metastasis [136].
The Hippo pathway and, most particularly, YAP and TAZ oncoproteins (Table 1), have a crucial role in gastric carcinogenesis, so therapeutic strategies involving their targeting could be of real efficiency in this poor prognosis, high relapse disease.
Table 1. Summary of YAP/TAZ expression, activation and regulation in GC.
Expression Levels of YAP/TAZ Regulation Reference
Overexpression of YAP Increase in pro-proliferation and pro-survival genes [86]
Upregulated through RUNX3 inactivation in GC [31]
Induced by METTL3 found highly expressed in GC [120]
Regulation by fixation of lncRNA RP11-323N12.5 on its promoter [126]
Induced by HER4 and increases EMT, GC cells proliferation, and HER2-therapy resistance [132]
Overactivation of YAP Activated by PAR1 through inhibition of LATS
Upregulation of stem-like properties		 [107]
Interacts with AMOTL1 to promote its nuclear translocation and activity [121]
Activation through MAPK-c-Jun pathway [122]
Inhibition is decreased through PP2A- inhibition of MST1/2 [123]
Overexpression of TAZ Co-localisation with ZEB1 EMT transcription factor
CSC tumorigenic properties		 [87]
Upregulation by MiR-125a-5p, leading to stimulation of genes involved in cell survival, EMT, invasion, and tumour growth [64]
Highly expressed in SRCC poorly undifferentiated GC [135]
YAP/TAZ overexpression in CSCs and residual cells after chemotherapy-treatment Overexpression of associated target genes [106]

References

  1. Justice, R.W.; Zilian, O.; Woods, D.F.; Noll, M.; Bryant, P.J. The Drosophila Tumor Suppressor Gene Warts Encodes a Homolog of Human Myotonic Dystrophy Kinase and Is Required for the Control of Cell Shape and Proliferation. Genes Dev. 1995, 9, 534–546.
  2. Xu, T.; Wang, W.; Zhang, S.; Stewart, R.A.; Yu, W. Identifying Tumor Suppressors in Genetic Mosaics: The Drosophila Lats Gene Encodes a Putative Protein Kinase. Dev. Camb. Engl. 1995, 121, 1053–1063.
  3. Piccolo, S.; Dupont, S.; Cordenonsi, M. The Biology of YAP/TAZ: Hippo Signaling and Beyond. Physiol. Rev. 2014, 94, 1287–1312.
  4. Udan, R.S.; Kango-Singh, M.; Nolo, R.; Tao, C.; Halder, G. Hippo Promotes Proliferation Arrest and Apoptosis in the Salvador/Warts Pathway. Nat. Cell Biol. 2003, 5, 914–920.
  5. Huang, J.; Wu, S.; Barrera, J.; Matthews, K.; Pan, D. The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005, 122, 421–434.
  6. Zhao, B.; Wei, X.; Li, W.; Udan, R.S.; Yang, Q.; Kim, J.; Xie, J.; Ikenoue, T.; Yu, J.; Li, L.; et al. Inactivation of YAP Oncoprotein by the Hippo Pathway Is Involved in Cell Contact Inhibition and Tissue Growth Control. Genes Dev. 2007, 21, 2747–2761.
  7. Dupont, S. Role of YAP/TAZ in Cell-Matrix Adhesion-Mediated Signalling and Mechanotransduction. Exp. Cell Res. 2016, 343, 42–53.
  8. Camargo, F.D.; Gokhale, S.; Johnnidis, J.B.; Fu, D.; Bell, G.W.; Jaenisch, R.; Brummelkamp, T.R. YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells. Curr. Biol. 2007, 17, 2054–2060.
  9. Dong, J.; Feldmann, G.; Huang, J.; Wu, S.; Zhang, N.; Comerford, S.A.; Gayyed, M.F.; Anders, R.A.; Maitra, A.; Pan, D. Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals. Cell 2007, 130, 1120–1133.
  10. Liu, C.-Y.; Zha, Z.-Y.; Zhou, X.; Zhang, H.; Huang, W.; Zhao, D.; Li, T.; Chan, S.W.; Lim, C.J.; Hong, W.; et al. The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase. J. Biol. Chem. 2010, 285, 37159.
  11. Zhou, D.; Zhang, Y.; Wu, H.; Barry, E.; Yin, Y.; Lawrence, E.; Dawson, D.; Willis, J.E.; Markowitz, S.D.; Camargo, F.D.; et al. Mst1 and Mst2 Protein Kinases Restrain Intestinal Stem Cell Proliferation and Colonic Tumorigenesis by Inhibition of Yes-Associated Protein (Yap) Overabundance. Proc. Natl. Acad. Sci. USA 2011, 108, E1312–E1320.
  12. Zanconato, F.; Cordenonsi, M.; Piccolo, S. YAP/TAZ at the Roots of Cancer. Cancer Cell 2016, 29, 783–803.
  13. Zanconato, F.; Battilana, G.; Cordenonsi, M.; Piccolo, S. YAP/TAZ as Therapeutic Targets in Cancer. Curr. Opin. Pharmacol. 2016, 29, 26–33.
  14. Plouffe, S.W.; Meng, Z.; Lin, K.C.; Lin, B.; Hong, A.W.; Chun, J.V.; Guan, K.-L. Characterization of Hippo Pathway Components by Gene Inactivation. Mol. Cell 2016, 64, 993–1008.
  15. Sudol, M. Yes-Associated Protein (YAP65) Is a Proline-Rich Phosphoprotein That Binds to the SH3 Domain of the Yes Proto-Oncogene Product. Oncogene 1994, 9, 2145–2152.
  16. Sudol, M.; Chen, H.I.; Bougeret, C.; Einbond, A.; Bork, P. Characterization of a Novel Protein-Binding Module--the WW Domain. FEBS Lett. 1995, 369, 67–71.
  17. Yagi, R.; Chen, L.F.; Shigesada, K.; Murakami, Y.; Ito, Y. A WW Domain-Containing Yes-Associated Protein (YAP) Is a Novel Transcriptional Co-Activator. EMBO J. 1999, 18, 2551–2562.
  18. Han, Y. Analysis of the Role of the Hippo Pathway in Cancer. J. Transl. Med. 2019, 17, 116.
  19. Zhao, B.; Ye, X.; Yu, J.; Li, L.; Li, W.; Li, S.; Yu, J.; Lin, J.D.; Wang, C.-Y.; Chinnaiyan, A.M.; et al. TEAD Mediates YAP-Dependent Gene Induction and Growth Control. Genes Dev. 2008, 22, 1962–1971.
  20. Heallen, T.; Morikawa, Y.; Leach, J.; Tao, G.; Willerson, J.T.; Johnson, R.L.; Martin, J.F. Hippo Signaling Impedes Adult Heart Regeneration. Dev. Camb. Engl. 2013, 140, 4683–4690.
  21. Heallen, T.; Zhang, M.; Wang, J.; Bonilla-Claudio, M.; Klysik, E.; Johnson, R.L.; Martin, J.F. Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size. Science 2011, 332, 458–461.
  22. Xin, M.; Kim, Y.; Sutherland, L.B.; Murakami, M.; Qi, X.; McAnally, J.; Porrello, E.R.; Mahmoud, A.I.; Tan, W.; Shelton, J.M.; et al. Hippo Pathway Effector Yap Promotes Cardiac Regeneration. Proc. Natl. Acad. Sci. USA 2013, 110, 13839–13844.
  23. von Gise, A.; Lin, Z.; Schlegelmilch, K.; Honor, L.B.; Pan, G.M.; Buck, J.N.; Ma, Q.; Ishiwata, T.; Zhou, B.; Camargo, F.D.; et al. YAP1, the Nuclear Target of Hippo Signaling, Stimulates Heart Growth through Cardiomyocyte Proliferation but Not Hypertrophy. Proc. Natl. Acad. Sci. USA 2012, 109, 2394–2399.
  24. Lei, Q.-Y.; Zhang, H.; Zhao, B.; Zha, Z.-Y.; Bai, F.; Pei, X.-H.; Zhao, S.; Xiong, Y.; Guan, K.-L. TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway. Mol. Cell. Biol. 2008, 28, 2426–2436.
  25. Ren, F.; Zhang, L.; Jiang, J. Hippo Signaling Regulates Yorkie Nuclear Localization and Activity through 14-3-3 Dependent and Independent Mechanisms. Dev. Biol. 2010, 337, 303–312.
  26. Zhao, B.; Li, L.; Tumaneng, K.; Wang, C.-Y.; Guan, K.-L. A Coordinated Phosphorylation by Lats and CK1 Regulates YAP Stability through SCFβ-TRCP. Genes Dev. 2010, 24, 72–85.
  27. Zygulska, A.L.; Krzemieniecki, K.; Pierzchalski, P. Hippo Pathway—Brief Overview of Its Relevance in Cancer. J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. 2017, 68, 311–335.
  28. Oka, T.; Remue, E.; Meerschaert, K.; Vanloo, B.; Boucherie, C.; Gfeller, D.; Bader, G.D.; Sidhu, S.S.; Vandekerckhove, J.; Gettemans, J.; et al. Functional Complexes between YAP2 and ZO-2 Are PDZ Domain-Dependent, and Regulate YAP2 Nuclear Localization and Signalling. Biochem. J. 2010, 432, 461–472.
  29. Remue, E.; Meerschaert, K.; Oka, T.; Boucherie, C.; Vandekerckhove, J.; Sudol, M.; Gettemans, J. TAZ Interacts with Zonula Occludens-1 and-2 Proteins in a PDZ-1 Dependent Manner. FEBS Lett. 2010, 584, 4175–4180.
  30. Lin, Z.; Guo, H.; Cao, Y.; Zohrabian, S.; Zhou, P.; Ma, Q.; VanDusen, N.; Guo, Y.; Zhang, J.; Stevens, S.M.; et al. Acetylation of VGLL4 Regulates Hippo-YAP Signaling and Postnatal Cardiac Growth. Dev. Cell 2016, 39, 466–479.
  31. Qiao, Y.; Lin, S.J.; Chen, Y.; Voon, D.C.-C.; Zhu, F.; Chuang, L.S.H.; Wang, T.; Tan, P.; Lee, S.C.; Yeoh, K.G.; et al. RUNX3 Is a Novel Negative Regulator of Oncogenic TEAD–YAP Complex in Gastric Cancer. Oncogene 2016, 35, 2664–2674.
  32. Yu, F.-X.; Zhao, B.; Guan, K.-L. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell 2015, 163, 811–828.
  33. Stokowski, R.P.; Cox, D.R. Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease-Causing Point Mutations. Am. J. Hum. Genet. 2000, 66, 873–891.
  34. Yi, C.; Troutman, S.; Fera, D.; Stemmer-Rachamimov, A.; Avila, J.L.; Christian, N.; Persson, N.L.; Shimono, A.; Speicher, D.W.; Marmorstein, R.; et al. A Tight Junction-Associated Merlin-Angiomotin Complex Mediates Merlin’s Regulation of Mitogenic Signaling and Tumor Suppressive Functions. Cancer Cell 2011, 19, 527–540.
  35. Yin, F.; Yu, J.; Zheng, Y.; Chen, Q.; Zhang, N.; Pan, D. Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2. Cell 2013, 154, 1342–1355.
  36. Benhamouche, S.; Curto, M.; Saotome, I.; Gladden, A.B.; Liu, C.-H.; Giovannini, M.; McClatchey, A.I. Nf2/Merlin Controls Progenitor Homeostasis and Tumorigenesis in the Liver. Genes Dev. 2010, 24, 1718–1730.
  37. Cordenonsi, M.; Zanconato, F.; Azzolin, L.; Forcato, M.; Rosato, A.; Frasson, C.; Inui, M.; Montagner, M.; Parenti, A.R.; Poletti, A.; et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells. Cell 2011, 147, 759–772.
  38. Wang, W.; Huang, J.; Chen, J. Angiomotin-like Proteins Associate with and Negatively Regulate YAP1. J. Biol. Chem. 2011, 286, 4364–4370.
  39. Zhao, B.; Li, L.; Lu, Q.; Wang, L.H.; Liu, C.-Y.; Lei, Q.; Guan, K.-L. Angiomotin Is a Novel Hippo Pathway Component That Inhibits YAP Oncoprotein. Genes Dev. 2011, 25, 51–63.
  40. Schlegelmilch, K.; Mohseni, M.; Kirak, O.; Pruszak, J.; Rodriguez, J.R.; Zhou, D.; Kreger, B.T.; Vasioukhin, V.; Avruch, J.; Brummelkamp, T.R.; et al. Yap1 Acts Downstream of α-Catenin to Control Epidermal Proliferation. Cell 2011, 144, 782–795.
  41. Silvis, M.R.; Kreger, B.T.; Lien, W.-H.; Klezovitch, O.; Rudakova, G.M.; Camargo, F.D.; Lantz, D.M.; Seykora, J.T.; Vasioukhin, V. α-Catenin Is a Tumor Suppressor That Controls Cell Accumulation by Regulating the Localization and Activity of the Transcriptional Coactivator Yap1. Sci. Signal. 2011, 4, ra33.
  42. Chen, D.; Sun, Y.; Wei, Y.; Zhang, P.; Rezaeian, A.H.; Teruya-Feldstein, J.; Gupta, S.; Liang, H.; Lin, H.-K.; Hung, M.-C.; et al. LIFR Is a Breast Cancer Metastasis Suppressor Upstream of the Hippo-YAP Pathway and a Prognostic Marker. Nat. Med. 2012, 18, 1511–1517.
  43. Seeneevassen, L.; Giraud, J.; Molina-Castro, S.; Sifré, E.; Tiffon, C.; Beauvoit, C.; Staedel, C.; Mégraud, F.; Lehours, P.; Martin, O.C.B.; et al. Leukaemia Inhibitory Factor (LIF) Inhibits Cancer Stem Cells Tumorigenic Properties through Hippo Kinases Activation in Gastric Cancer. Cancers 2020, 12, 2011.
  44. Dai, X.; She, P.; Chi, F.; Feng, Y.; Liu, H.; Jin, D.; Zhao, Y.; Guo, X.; Jiang, D.; Guan, K.-L.; et al. Phosphorylation of Angiomotin by Lats1/2 Kinases Inhibits F-Actin Binding, Cell Migration, and Angiogenesis. J. Biol. Chem. 2013, 288, 34041–34051.
  45. Ribeiro, P.S.; Josué, F.; Wepf, A.; Wehr, M.C.; Rinner, O.; Kelly, G.; Tapon, N.; Gstaiger, M. Combined Functional Genomic and Proteomic Approaches Identify a PP2A Complex as a Negative Regulator of Hippo Signaling. Mol. Cell 2010, 39, 521–534.
  46. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The next Generation. Cell 2011, 144, 646–674.
  47. Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022, 12, 31–46.
  48. Lamar, J.M.; Stern, P.; Liu, H.; Schindler, J.W.; Jiang, Z.-G.; Hynes, R.O. The Hippo Pathway Target, YAP, Promotes Metastasis through Its TEAD-Interaction Domain. Proc. Natl. Acad. Sci. USA 2012, 109, E2441–E2450.
  49. Plouffe, S.W.; Lin, K.C.; Moore, J.L.; Tan, F.E.; Ma, S.; Ye, Z.; Qiu, Y.; Ren, B.; Guan, K.-L. The Hippo Pathway Effector Proteins YAP and TAZ Have Both Distinct and Overlapping Functions in the Cell. J. Biol. Chem. 2018, 293, 11230–11240.
  50. Zheng, X.; Chen, L.; Zhou, Y.; Wang, Q.; Zheng, Z.; Xu, B.; Wu, C.; Zhou, Q.; Hu, W.; Wu, C.; et al. A Novel Protein Encoded by a Circular RNA CircPPP1R12A Promotes Tumor Pathogenesis and Metastasis of Colon Cancer via Hippo-YAP Signaling. Mol. Cancer 2019, 18, 47.
  51. Xiang, L.; Gilkes, D.M.; Hu, H.; Luo, W.; Bullen, J.W.; Liang, H.; Semenza, G.L. HIF-1α and TAZ Serve as Reciprocal Co-Activators in Human Breast Cancer Cells. Oncotarget 2015, 6, 11768–11778.
  52. Bendinelli, P.; Maroni, P.; Matteucci, E.; Luzzati, A.; Perrucchini, G.; Desiderio, M.A. Hypoxia Inducible Factor-1 Is Activated by Transcriptional Co-Activator with PDZ-Binding Motif (TAZ) versus WWdomain-Containing Oxidoreductase (WWOX) in Hypoxic Microenvironment of Bone Metastasis from Breast Cancer. Eur. J. Cancer Oxf. Engl. 1990 2013, 49, 2608–2618.
  53. Lehmann, W.; Mossmann, D.; Kleemann, J.; Mock, K.; Meisinger, C.; Brummer, T.; Herr, R.; Brabletz, S.; Stemmler, M.P.; Brabletz, T. ZEB1 Turns into a Transcriptional Activator by Interacting with YAP1 in Aggressive Cancer Types. Nat. Commun. 2016, 7, 10498.
  54. Li, C.; Wang, S.; Xing, Z.; Lin, A.; Liang, K.; Song, J.; Hu, Q.; Yao, J.; Chen, Z.; Park, P.K.; et al. A ROR1-HER3-LncRNA Signalling Axis Modulates the Hippo-YAP Pathway to Regulate Bone Metastasis. Nat. Cell Biol. 2017, 19, 106–119.
  55. Chen, Q.; Zhang, N.; Gray, R.S.; Li, H.; Ewald, A.J.; Zahnow, C.A.; Pan, D. A Temporal Requirement for Hippo Signaling in Mammary Gland Differentiation, Growth, and Tumorigenesis. Genes Dev. 2014, 28, 432–437.
  56. Nishio, M.; Hamada, K.; Kawahara, K.; Sasaki, M.; Noguchi, F.; Chiba, S.; Mizuno, K.; Suzuki, S.O.; Dong, Y.; Tokuda, M.; et al. Cancer Susceptibility and Embryonic Lethality in Mob1a/1b Double-Mutant Mice. J. Clin. Investig. 2012, 122, 4505–4518.
  57. Calvo, F.; Ege, N.; Grande-Garcia, A.; Hooper, S.; Jenkins, R.P.; Chaudhry, S.I.; Harrington, K.; Williamson, P.; Moeendarbary, E.; Charras, G.; et al. Mechanotransduction and YAP-Dependent Matrix Remodelling Is Required for the Generation and Maintenance of Cancer-Associated Fibroblasts. Nat. Cell Biol. 2013, 15, 637–646.
  58. Yao, F.; Liu, H.; Li, Z.; Zhong, C.; Fang, W. Down-Regulation of LATS2 in Non-Small Cell Lung Cancer Promoted the Growth and Motility of Cancer Cells. Tumor Biol. 2015, 36, 2049–2057.
  59. Lin, C.-W.; Chang, Y.-L.; Chang, Y.-C.; Lin, J.-C.; Chen, C.-C.; Pan, S.-H.; Wu, C.-T.; Chen, H.-Y.; Yang, S.-C.; Hong, T.-M.; et al. MicroRNA-135b Promotes Lung Cancer Metastasis by Regulating Multiple Targets in the Hippo Pathway and LZTS1. Nat. Commun. 2013, 4, 1877.
  60. Kurppa, K.J.; Liu, Y.; To, C.; Zhang, T.; Fan, M.; Vajdi, A.; Knelson, E.H.; Xie, Y.; Lim, K.; Cejas, P.; et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell 2020, 37, 104–122.
  61. You, B.; Yang, Y.-L.; Xu, Z.; Dai, Y.; Liu, S.; Mao, J.-H.; Tetsu, O.; Li, H.; Jablons, D.M.; You, L. Inhibition of ERK1/2 down-Regulates the Hippo/YAP Signaling Pathway in Human NSCLC Cells. Oncotarget 2015, 6, 4357–4368.
  62. Lee, K.-P.; Lee, J.-H.; Kim, T.-S.; Kim, T.-H.; Park, H.-D.; Byun, J.-S.; Kim, M.-C.; Jeong, W.-I.; Calvisi, D.F.; Kim, J.-M.; et al. The Hippo-Salvador Pathway Restrains Hepatic Oval Cell Proliferation, Liver Size, and Liver Tumorigenesis. Proc. Natl. Acad. Sci. USA 2010, 107, 8248–8253.
  63. Hu, Y.; Yang, C.; Yang, S.; Cheng, F.; Rao, J.; Wang, X. MiR-665 Promotes Hepatocellular Carcinoma Cell Migration, Invasion, and Proliferation by Decreasing Hippo Signaling through Targeting PTPRB. Cell Death Dis. 2018, 9, 954.
  64. Lee, N.-H.; Kim, S.J.; Hyun, J. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer. Biomedicines 2021, 9, 347.
  65. Cheng, L.; Wang, H.; Han, S. MiR-3910 Promotes the Growth and Migration of Cancer Cells in the Progression of Hepatocellular Carcinoma. Dig. Dis. Sci. 2017, 62, 2812–2820.
  66. Shi, X.; Zhu, H.-R.; Liu, T.-T.; Shen, X.-Z.; Zhu, J.-M. The Hippo Pathway in Hepatocellular Carcinoma: Non-Coding RNAs in Action. Cancer Lett. 2017, 400, 175–182.
  67. Yang, X.; Yu, J.; Yin, J.; Xiang, Q.; Tang, H.; Lei, X. MiR-195 Regulates Cell Apoptosis of Human Hepatocellular Carcinoma Cells by Targeting LATS2. Die Pharm. Int. J. Pharm. Sci. 2012, 67, 645–651.
  68. Liu, Y.; Wang, X.; Yang, Y. Hepatic Hippo Signaling Inhibits Development of Hepatocellular Carcinoma. Clin. Mol. Hepatol. 2020, 26, 742–750.
  69. Wang, J.; Ma, L.; Weng, W.; Qiao, Y.; Zhang, Y.; He, J.; Wang, H.; Xiao, W.; Li, L.; Chu, Q.; et al. Mutual Interaction between YAP and CREB Promotes Tumorigenesis in Liver Cancer. Hepatology 2013, 58, 1011–1020.
  70. Li, L.; Wang, J.; Zhang, Y.; Zhang, Y.; Ma, L.; Weng, W.; Qiao, Y.; Xiao, W.; Wang, H.; Yu, W.; et al. MEK1 Promotes YAP and Their Interaction Is Critical for Tumorigenesis in Liver Cancer. FEBS Lett. 2013, 587, 3921–3927.
  71. Zhang, X.; Yang, L.; Szeto, P.; Abali, G.K.; Zhang, Y.; Kulkarni, A.; Amarasinghe, K.; Li, J.; Vergara, I.A.; Molania, R.; et al. The Hippo Pathway Oncoprotein YAP Promotes Melanoma Cell Invasion and Spontaneous Metastasis. Oncogene 2020, 39, 5267–5281.
  72. Goel, H.; Mathur, R.; Syeda, S.; Shrivastava, A.; Kumar Jha, A. Promoter Hypermethylation of LATS1 Gene in Oral Squamous Cell Carcinoma (OSCC) among North Indian Population. Asian Pac. J. Cancer Prev. APJCP 2021, 22, 977–982.
  73. Ladiz, M.A.R.; Najafi, M.; Kordi-Tamandani, D.M. Contribution of LATS1 and LATS2 Promoter Methylation in OSCC Development. J. Cell Commun. Signal. 2017, 11, 49–55.
  74. Shao, D.D.; Xue, W.; Krall, E.B.; Bhutkar, A.; Piccioni, F.; Wang, X.; Schinzel, A.C.; Sood, S.; Rosenbluh, J.; Kim, J.W.; et al. KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell 2014, 158, 171–184.
  75. Rosenbluh, J.; Nijhawan, D.; Cox, A.G.; Li, X.; Neal, J.T.; Schafer, E.J.; Zack, T.I.; Wang, X.; Tsherniak, A.; Schinzel, A.C.; et al. β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis. Cell 2012, 151, 1457–1473.
  76. Azzolin, L.; Panciera, T.; Soligo, S.; Enzo, E.; Bicciato, S.; Dupont, S.; Bresolin, S.; Frasson, C.; Basso, G.; Guzzardo, V.; et al. YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response. Cell 2014, 158, 157–170.
  77. Varelas, X.; Miller, B.W.; Sopko, R.; Song, S.; Gregorieff, A.; Fellouse, F.A.; Sakuma, R.; Pawson, T.; Hunziker, W.; McNeill, H.; et al. The Hippo Pathway Regulates Wnt/Beta-Catenin Signaling. Dev. Cell 2010, 18, 579–591.
  78. Al-Moujahed, A.; Brodowska, K.; Stryjewski, T.; Efstathiou, N.; Vasilikos, I.; Cichy, J.; Miller, J.; Gragoudas, E.; Vavvas, D. Verteporfin Inhibits Growth of Human Glioma in Vitro without Light Activation. Sci. Rep. 2017, 7, 7602.
  79. Brodowska, K.; Al-Moujahed, A.; Marmalidou, A.; Meyer Zu Horste, M.; Cichy, J.; Miller, J.; Gragoudas, E.; Vavvas, D. The Clinically Used Photosensitizer Verteporfin (VP) Inhibits YAP-TEAD and Human Retinoblastoma Cell Growth in Vitro without Light Activation. Exp. Eye Res. 2014, 124, 67–73.
  80. Dasari, V.R.; Mazack, V.; Feng, W.; Nash, J.; Carey, D.J.; Gogoi, R. Verteporfin Exhibits YAP-Independent Anti-Proliferative and Cytotoxic Effects in Endometrial Cancer Cells. Oncotarget 2017, 8, 28628–28640.
  81. Nguyen, C.; Yi, C. YAP/TAZ Signaling and Resistance to Cancer Therapy. Trends Cancer 2019, 5, 283–296.
  82. Zeng, R.; Dong, J. The Hippo Signaling Pathway in Drug Resistance in Cancer. Cancers 2021, 13, 318.
  83. Dong, L.; Lin, F.; Wu, W.; Liu, Y.; Huang, W. Verteporfin Inhibits YAP-Induced Bladder Cancer Cell Growth and Invasion via Hippo Signaling Pathway. Int. J. Med. Sci. 2018, 15, 645–652.
  84. Janse van Rensburg, H.J.; Yang, X. The Roles of the Hippo Pathway in Cancer Metastasis. Cell. Signal. 2016, 28, 1761–1772.
  85. Pan, Z.; Tian, Y.; Niu, G.; Cao, C. The Emerging Role of GC-MSCs in the Gastric Cancer Microenvironment: From Tumor to Tumor Immunity. Stem Cells Int. 2019, 2019, 8071842.
  86. Molina-Castro, S.E.; Tiffon, C.; Giraud, J.; Boeuf, H.; Sifre, E.; Giese, A.; Belleannée, G.; Lehours, P.; Bessède, E.; Mégraud, F.; et al. The Hippo Kinase LATS2 Controls Helicobacter Pylori-Induced Epithelial-Mesenchymal Transition and Intestinal Metaplasia in Gastric Mucosa. Cell. Mol. Gastroenterol. Hepatol. 2020, 9, 257–276.
  87. Tiffon, C.; Giraud, J.; Molina-Castro, S.E.; Peru, S.; Seeneevassen, L.; Sifré, E.; Staedel, C.; Bessède, E.; Dubus, P.; Mégraud, F.; et al. TAZ Controls Helicobacter Pylori-Induced Epithelial-Mesenchymal Transition and Cancer Stem Cell-Like Invasive and Tumorigenic Properties. Cells 2020, 9, 1462.
  88. Seeneevassen, L.; Bessède, E.; Mégraud, F.; Lehours, P.; Dubus, P.; Varon, C. Gastric Cancer: Advances in Carcinogenesis Research and New Therapeutic Strategies. Int. J. Mol. Sci. 2021, 22, 3418.
  89. Varon, C.; Azzi-Martin, L.; Khalid, S.; Seeneevassen, L.; Ménard, A.; Spuul, P. Helicobacters and Cancer, Not Only Gastric Cancer? Semin. Cancer Biol. 2021, in press.
  90. Xu, Z.P.; Zhu, J.S.; Zhang, Q.; Wang, X.Y. A Breakdown of the Hippo Pathway in Gastric Cancer. Hepatogastroenterology 2011, 58, 1611–1617.
  91. Zhou, G.-X.; Li, X.-Y.; Zhang, Q.; Zhao, K.; Zhang, C.-P.; Xue, C.-H.; Yang, K.; Tian, Z.-B. Effects of the Hippo Signaling Pathway in Human Gastric Cancer. Asian Pac. J. Cancer Prev. 2013, 14, 5199–5205.
  92. Sun, D.; Li, X.; He, Y.; Li, W.; Wang, Y.; Wang, H.; Jiang, S.; Xin, Y. YAP1 Enhances Cell Proliferation, Migration, and Invasion of Gastric Cancer in Vitro and in Vivo. Oncotarget 2016, 7, 81062–81076.
  93. Kang, W.; Tong, J.H.M.; Chan, A.W.H.; Lee, T.-L.; Lung, R.W.M.; Leung, P.P.S.; So, K.K.Y.; Wu, K.; Fan, D.; Yu, J.; et al. Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2011, 17, 2130–2139.
  94. Song, M.; Cheong, J.-H.; Kim, H.; Noh, S.H.; Kim, H. Nuclear Expression of Yes-Associated Protein 1 Correlates with Poor Prognosis in Intestinal Type Gastric Cancer. Anticancer Res. 2012, 32, 3827–3834.
  95. Song, M.; Rabkin, C.S.; Camargo, M.C. Gastric Cancer: An Evolving Disease. Curr. Treat. Options Gastroenterol. 2018, 16, 561–569.
  96. Jiao, S.; Wang, H.; Shi, Z.; Dong, A.; Zhang, W.; Song, X.; He, F.; Wang, Y.; Zhang, Z.; Wang, W.; et al. A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer. Cancer Cell 2014, 25, 166–180.
  97. Lánczky, A.; Győrffy, B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J. Med. Internet Res. 2021, 23, e27633.
  98. Liu, Y.; Xin, Y.; Ye, F.; Wang, W.; Lu, Q.; Kaplan, H.J.; Dean, D.C. Taz-Tead1 Links Cell-Cell Contact to Zeb1 Expression, Proliferation, and Dedifferentiation in Retinal Pigment Epithelial Cells. Investig. Ophthalmol. Vis. Sci. 2010, 51, 3372–3378.
  99. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective Identification of Tumorigenic Breast Cancer Cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983–3988.
  100. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a Cancer Stem Cell in Human Brain Tumors. Cancer Res. 2003, 63, 5821–5828.
  101. Ricci-Vitiani, L.; Lombardi, D.G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria, R. Identification and Expansion of Human Colon-Cancer-Initiating Cells. Nature 2007, 445, 111–115.
  102. Takaishi, S.; Okumura, T.; Tu, S.; Wang, S.S.W.; Shibata, W.; Vigneshwaran, R.; Gordon, S.A.K.; Shimada, Y.; Wang, T.C. Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44. Stem Cells Dayt. Ohio 2009, 27, 1006–1020.
  103. Fukuda, K.; Saikawa, Y.; Ohashi, M.; Kumagai, K.; Kitajima, M.; Okano, H.; Matsuzaki, Y.; Kitagawa, Y. Tumor Initiating Potential of Side Population Cells in Human Gastric Cancer. Int. J. Oncol. 2009, 34, 1201–1207.
  104. Nguyen, P.H.; Giraud, J.; Chambonnier, L.; Dubus, P.; Wittkop, L.; Belleannée, G.; Collet, D.; Soubeyran, I.; Evrard, S.; Rousseau, B.; et al. Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma. Clin. Cancer Res. 2017, 23, 1586–1597.
  105. Bessède, E.; Staedel, C.; Acuña Amador, L.A.; Nguyen, P.H.; Chambonnier, L.; Hatakeyama, M.; Belleannée, G.; Mégraud, F.; Varon, C. Helicobacter Pylori Generates Cells with Cancer Stem Cell Properties via Epithelial-Mesenchymal Transition-like Changes. Oncogene 2014, 33, 4123–4131.
  106. Giraud, J.; Molina-Castro, S.; Seeneevassen, L.; Sifré, E.; Izotte, J.; Tiffon, C.; Staedel, C.; Boeuf, H.; Fernandez, S.; Barthelemy, P.; et al. Verteporfin Targeting YAP1/TAZ-TEAD Transcriptional Activity Inhibits the Tumorigenic Properties of Gastric Cancer Stem Cells. Int. J. Cancer 2019, 146, 2255–2267.
  107. Fujimoto, D.; Ueda, Y.; Hirono, Y.; Goi, T.; Yamaguchi, A. PAR1 Participates in the Ability of Multidrug Resistance and Tumorigenesis by Controlling Hippo-YAP Pathway. Oncotarget 2015, 6, 34788–34799.
  108. Song, S.; Wang, Z.; Li, Y.; Ma, L.; Jin, J.; Scott, A.W.; Xu, Y.; Estrella, J.S.; Song, Y.; Liu, B.; et al. PPARδ Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression. Mol. Cancer Res. 2020, 18, 390–402.
  109. Song, S.; Ajani, J.A.; Honjo, S.; Maru, D.M.; Chen, Q.; Scott, A.W.; Heallen, T.R.; Xiao, L.; Hofstetter, W.L.; Weston, B.; et al. Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties. Cancer Res. 2014, 74, 4170–4182.
  110. Choi, I.J.; Kook, M.-C.; Kim, Y.-I.; Cho, S.-J.; Lee, J.Y.; Kim, C.G.; Park, B.; Nam, B.-H. Helicobacter Pylori Therapy for the Prevention of Metachronous Gastric Cancer. N. Engl. J. Med. 2018, 378, 1085–1095.
  111. Zhang, J.; Wang, G.; Chu, S.-J.; Zhu, J.-S.; Zhang, R.; Lu, W.-W.; Xia, L.-Q.; Lu, Y.-M.; Da, W.; Sun, Q. Loss of Large Tumor Suppressor 1 Promotes Growth and Metastasis of Gastric Cancer Cells through Upregulation of the YAP Signaling. Oncotarget 2016, 7, 16180–16193.
  112. Yue, G.; Sun, X.; Gimenez-Capitan, A.; Shen, J.; Yu, L.; Teixido, C.; Guan, W.; Rosell, R.; Liu, B.; Wei, J. TAZ Is Highly Expressed in Gastric Signet Ring Cell Carcinoma. BioMed Res. Int. 2014, 2014, 393064.
  113. Guo, Z.; Zhou, K.; Wang, Q.; Huang, Y.; Ji, J.; Peng, Y.; Zhang, X.; Zheng, T.; Zhang, Z.; Chong, D.; et al. The Transcription Factor RUNX2 Fuels YAP1 Signaling and Gastric Cancer Tumorigenesis. Cancer Sci. 2021, 112, 3533–3544.
  114. Guo, Z.-J.; Yang, L.; Qian, F.; Wang, Y.-X.; Yu, X.; Ji, C.-D.; Cui, W.; Xiang, D.-F.; Zhang, X.; Zhang, P.; et al. Transcription Factor RUNX2 Up-Regulates Chemokine Receptor CXCR4 to Promote Invasive and Metastatic Potentials of Human Gastric Cancer. Oncotarget 2016, 7, 20999–21012.
  115. Fujita, T.; Chiwaki, F.; Takahashi, R.; Aoyagi, K.; Yanagihara, K.; Nishimura, T.; Tamaoki, M.; Komatsu, M.; Komatsuzaki, R.; Matsusaki, K.; et al. Identification and Characterization of CXCR4-Positive Gastric Cancer Stem Cells. PLoS ONE 2015, 10, e0130808.
  116. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer. Cell Stem Cell 2007, 1, 313–323.
  117. Kucia, M.; Reca, R.; Miekus, K.; Wanzeck, J.; Wojakowski, W.; Janowska-Wieczorek, A.; Ratajczak, J.; Ratajczak, M.Z. Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF-1–CXCR4 Axis. Stem Cells 2005, 23, 879–894.
  118. Kim, J.; Takeuchi, H.; Lam, S.T.; Turner, R.R.; Wang, H.-J.; Kuo, C.; Foshag, L.; Bilchik, A.J.; Hoon, D.S.B. Chemokine Receptor CXCR4 Expression in Colorectal Cancer Patients Increases the Risk for Recurrence and for Poor Survival. J. Clin. Oncol. 2005, 23, 2744–2753.
  119. Müller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M.E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S.N.; et al. Involvement of Chemokine Receptors in Breast Cancer Metastasis. Nature 2001, 410, 50–56.
  120. Zhou, W.; Xian, Q.; Wang, Q.; Wu, C.; Yan, H.; Li, X.; Lu, L.; Wu, C.; Zhu, D.; Xu, X.; et al. M6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the M6A Modification of YAP1. J. Oncol. 2021, 2021, 8875424.
  121. Zhou, Y.; Zhang, J.; Li, H.; Huang, T.; Wong, C.C.; Wu, F.; Wu, M.; Weng, N.; Liu, L.; Cheng, A.S.L.; et al. AMOTL1 Enhances YAP1 Stability and Promotes YAP1-Driven Gastric Oncogenesis. Oncogene 2020, 39, 4375–4389.
  122. Zhang, J.; Wong, C.C.; Leung, K.T.; Wu, F.; Zhou, Y.; Tong, J.H.M.; Chan, R.C.K.; Li, H.; Wang, Y.; Yan, H.; et al. FGF18-FGFR2 Signaling Triggers the Activation of c-Jun-YAP1 Axis to Promote Carcinogenesis in a Subgroup of Gastric Cancer Patients and Indicates Translational Potential. Oncogene 2020, 39, 6647–6663.
  123. Tang, Y.; Fang, G.; Guo, F.; Zhang, H.; Chen, X.; An, L.; Chen, M.; Zhou, L.; Wang, W.; Ye, T.; et al. Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer. Cancer Cell 2020, 38, 115–128.e9.
  124. Kang, W.; Huang, T.; Zhou, Y.; Zhang, J.; Lung, R.W.M.; Tong, J.H.M.; Chan, A.W.H.; Zhang, B.; Wong, C.C.; Wu, F.; et al. MiR-375 Is Involved in Hippo Pathway by Targeting YAP1/TEAD4-CTGF Axis in Gastric Carcinogenesis. Cell Death Dis. 2018, 9, 92.
  125. Belair, C.; Baud, J.; Chabas, S.; Sharma, C.M.; Vogel, J.; Staedel, C.; Darfeuille, F. Helicobacter Pylori Interferes with an Embryonic Stem Cell Micro RNA Cluster to Block Cell Cycle Progression. Silence 2011, 2, 7.
  126. Wang, J.; Huang, F.; Shi, Y.; Zhang, Q.; Xu, S.; Yao, Y.; Jiang, R. RP11-323N12.5 Promotes the Malignancy and Immunosuppression of Human Gastric Cancer by Increasing YAP1 Transcription. Gastric Cancer 2020, 24, 85–102.
  127. Liu, K.; Wang, B.-J.; Han, W.; Chi, C.-H.; Gu, C.; Wang, Y.; Fu, X.; Huang, W.; Liu, Z.; Song, X. CFIm25-Regulated LncRNA Acv3UTR Promotes Gastric Tumorigenesis via MiR-590-5p/YAP1 Axis. Oncogene 2020, 39, 3075–3088.
  128. Wang, H.; Di, X.; Bi, Y.; Sun, S.; Wang, T. Long Non-Coding RNA LINC00649 Regulates YES-Associated Protein 1 (YAP1)/Hippo Pathway to Accelerate Gastric Cancer (GC) Progression via Sequestering MiR-16-5p. Bioengineered 2021, 12, 1791–1802.
  129. Sun, D.; Wang, Y.; Wang, H.; Xin, Y. The Novel Long Non-Coding RNA LATS2-AS1-001 Inhibits Gastric Cancer Progression by Regulating the LATS2/YAP1 Signaling Pathway via Binding to EZH2. Cancer Cell Int. 2020, 20, 204.
  130. Liu, J.; Zhao, X.; Wang, K.; Zhang, X.; Yu, Y.; Lv, Y.; Zhang, S.; Zhang, L.; Guo, Y.; Li, Y.; et al. A Novel YAP1/SLC35B4 Regulatory Axis Contributes to Proliferation and Progression of Gastric Carcinoma. Cell Death Dis. 2019, 10, 452.
  131. Huang, S.; Cao, Y.; Guo, H.; Yao, Y.; Li, L.; Chen, J.; Li, J.; Xiang, X.; Deng, J.; Xiong, J. Up-Regulated Acylglycerol Kinase (AGK) Expression Associates with Gastric Cancer Progression through the Formation of a Novel YAP1-AGK-Positive Loop. J. Cell. Mol. Med. 2020, 24, 11133–11145.
  132. Shi, J.; Li, F.; Yao, X.; Mou, T.; Xu, Z.; Han, Z.; Chen, S.; Li, W.; Yu, J.; Qi, X.; et al. The HER4-YAP1 Axis Promotes Trastuzumab Resistance in HER2-Positive Gastric Cancer by Inducing Epithelial and Mesenchymal Transition. Oncogene 2018, 37, 3022–3038.
  133. Lu, T.; Sun, L.; Zhu, X. Yes-Associated Protein Enhances Proliferation and Attenuates Sensitivity to Cisplatin in Human Gastric Cancer Cells. Biomed. Pharmacother. Biomed. Pharmacother. 2018, 105, 1269–1275.
  134. Ge, L.; Li, D.-S.; Chen, F.; Feng, J.-D.; Li, B.; Wang, T.-J. TAZ Overexpression Is Associated with Epithelial-Mesenchymal Transition in Cisplatin-Resistant Gastric Cancer Cells. Int. J. Oncol. 2017, 51, 307–315.
  135. Hasegawa, T.; Sugihara, T.; Hoshino, Y.; Tarumoto, R.; Matsuki, Y.; Kanda, T.; Takata, T.; Nagahara, T.; Matono, T.; Isomoto, H. Photosensitizer Verteporfin Inhibits the Growth of YAP- and TAZ-Dominant Gastric Cancer Cells by Suppressing the Anti-Apoptotic Protein Survivin in a Light-Independent Manner. Oncol. Lett. 2021, 22, 703.
  136. Li, M.; Rao, X.; Cui, Y.; Zhang, L.; Li, X.; Wang, B.; Zheng, Y.; Teng, L.; Zhou, T.; Zhuo, W. The Keratin 17/YAP/IL6 Axis Contributes to E-Cadherin Loss and Aggressiveness of Diffuse Gastric Cancer. Oncogene 2022, 41, 770–781.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Cell Biology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Lornella Seeneevassen
,
Pierre Dubus
,
Caroline Gronnier
,
Christine Varon
View Times: 817
Entry Collection: Gastrointestinal Disease
Revisions: 2 times (View History)
Update Date: 16 May 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback